Christine E. Swenson

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz et al. · Journal of Clinical Oncology · 2011 · 299 citations · Full text

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

Gerald Batist, Karen A. Gelmon, Kim N. et al. · Clinical Cancer Research · 2009 · 210 citations · Full text

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

K. Mross, Bernward Niemann, Ulrich Massing et al. · Cancer Chemotherapy and Pharmacology · 2004 · 135 citations

Solid Tumors, Medicine, Pharmacology +7

Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)

Christine E. Swenson, Walter R. Perkins, Patricia J. Roberts et al. · The Breast · 2001 · 130 citations

Lipid Preparation, Liposome Technology, Lipid Chemistry +2

Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice

S P Klemens, Michael H. Cynamon, Christine E. Swenson et al. · Antimicrobial Agents and Chemotherapy · 1990 · 121 citations · Full text